Home › Prescription medicine › Ajanta Pharma USA Inc — Ranolazine…
Ajanta Pharma USA Inc — Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only
Do not stop taking this without speaking to your pharmacist or doctor.
What’s wrong
Failed Dissolution Specifications: below specification
The Recall Registry rates this serious — FDA Class II: temporary or medically reversible health harm.
What to do
Check the lot numbers below against what you have. Do not stop taking a prescription medicine because of a recall without speaking to your pharmacist or doctor first — for many medicines stopping is more harmful than continuing, and they can tell you whether yours is affected and what to do about it.
Who to contact: Recalling firm: Ajanta Pharma USA Inc
The product
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02
Details
- Recall date
- September 17, 2026
- Brand
- Ajanta Pharma USA Inc
Nationwide in the US
The official notice
This recall was issued by the U.S. Food and Drug Administration. The Recall Registry summarises it — always confirm the details at the source.
Their exact wording: “Ajanta Pharma USA Inc — Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02”
Worried about the other things in your house? You can write down what you have and be told if one is recalled — or, if you sell second-hand, check your whole stock at once.
Filed under: Prescription medicine